{"id":"tmc125","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TMC125 works by binding to the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. This action inhibits the replication of the virus, thereby reducing the viral load in the body.","oneSentence":"TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:15.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT00980538","phase":"PHASE3","title":"TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Sciences Ireland UC","startDate":"2009-12-09","conditions":"HIV Infections, HIV-1","enrollment":180},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04208373","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT06155019","phase":"","title":"Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2023-12-08","conditions":"HIV Infections","enrollment":109},{"nctId":"NCT04273165","phase":"PHASE2","title":"Safety and Efficacy of Etravirine in Friedreich Ataxia Patients","status":"COMPLETED","sponsor":"IRCCS Eugenio Medea","startDate":"2020-09-17","conditions":"Friedreich Ataxia","enrollment":30},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT05506605","phase":"PHASE4","title":"Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-12-12","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT04194021","phase":"","title":"Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir","status":"UNKNOWN","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2019-01-01","conditions":"HIV/AIDS","enrollment":871},{"nctId":"NCT01822522","phase":"PHASE1","title":"Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-21","conditions":"Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT01276236","phase":"PHASE2","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03-09","conditions":"Kaposi's Sarcoma","enrollment":13},{"nctId":"NCT04334551","phase":"PHASE4","title":"HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance","status":"UNKNOWN","sponsor":"Clinique du Quartier Latin","startDate":"2020-06-23","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT03369743","phase":"","title":"Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2018-01-02","conditions":"HIV Infections","enrollment":125},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01034917","phase":"PHASE3","title":"Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-12","conditions":"HIV","enrollment":43},{"nctId":"NCT01347658","phase":"NA","title":"Drug Interactions Between Echinacea Purpurea and Etravirine","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-04","conditions":"HIV","enrollment":15},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT00823979","phase":"PHASE2","title":"A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-03-25","conditions":"HIV-1","enrollment":105},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00855335","phase":"PHASE3","title":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2009-04-09","conditions":"HIV, HIV Infections, Pregnancy","enrollment":77},{"nctId":"NCT02818348","phase":"PHASE1","title":"Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2016-06","conditions":"HIV-1 Infection","enrollment":30},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT01199731","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-10-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT00855413","phase":"PHASE4","title":"HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-03","conditions":"Acute HIV Infection, HIV Infections","enrollment":15},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT01076179","phase":"","title":"Kaletra in Combination With Antiretroviral Agents","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Human Immunodeficiency Virus","enrollment":502},{"nctId":"NCT01045369","phase":"PHASE4","title":"A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects","status":"COMPLETED","sponsor":"Therapeutic Concepts","startDate":"2010-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01814722","phase":"","title":"Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-09","conditions":"Human Immunodeficiency Virus","enrollment":63},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT00959894","phase":"PHASE2","title":"Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-09","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01741844","phase":"","title":"A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-09","conditions":"Acquired Immune Deficiency Syndrome","enrollment":57},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT00354627","phase":"PHASE3","title":"The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2006-01","conditions":"HIV-1","enrollment":5178},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00534352","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-01","conditions":"HIV-1 Infection","enrollment":23},{"nctId":"NCT01118871","phase":"PHASE4","title":"The First Failure Study","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2010-05","conditions":"HIV, HIV Infections","enrollment":3},{"nctId":"NCT01422330","phase":"PHASE4","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-09","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":211},{"nctId":"NCT01428986","phase":"","title":"Safety Study of Maraviroc's Effect on Human Osteoclasts","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2009-11","conditions":"HIV Infections, AIDS","enrollment":16},{"nctId":"NCT01625169","phase":"NA","title":"Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2010-04","conditions":"HIV","enrollment":9},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT01615601","phase":"","title":"An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":77},{"nctId":"NCT00359021","phase":"PHASE3","title":"An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2006-06","conditions":"HIV-1","enrollment":503},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01543035","phase":"PHASE3","title":"Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs","status":"COMPLETED","sponsor":"Calmy Alexandra","startDate":"2011-12","conditions":"HIV Infection","enrollment":34},{"nctId":"NCT01199939","phase":"PHASE2","title":"A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2010-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":54},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT00460746","phase":"PHASE3","title":"Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2007-05","conditions":"HIV","enrollment":10},{"nctId":"NCT01427504","phase":"NA","title":"Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-08","conditions":"Hepatitis C, HIV","enrollment":26},{"nctId":"NCT00128830","phase":"PHASE2","title":"A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":211},{"nctId":"NCT01876966","phase":"PHASE1","title":"Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2011-03","conditions":"HIV","enrollment":33},{"nctId":"NCT01189695","phase":"PHASE4","title":"Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-12","conditions":"HIV, AIDS, Lopinavir","enrollment":63},{"nctId":"NCT00903682","phase":"PHASE2","title":"A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-06","conditions":"HIV Infection, HIV, Acquired Immunodeficiency Syndrome","enrollment":157},{"nctId":"NCT01090648","phase":"PHASE1","title":"TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-03","conditions":"HIV-Infections","enrollment":49},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01336829","phase":"PHASE1","title":"TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-03","conditions":"Hepatitis C, HIV","enrollment":33},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00867152","phase":"PHASE1","title":"GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-04","conditions":"Healthy Volunteer","enrollment":17},{"nctId":"NCT00782301","phase":"PHASE4","title":"Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT01437241","phase":"","title":"Etravirine Plus 2 Analogs in HIV-infected Patients","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2009-01","conditions":"HIV-1-infection","enrollment":175},{"nctId":"NCT00792584","phase":"NA","title":"Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2008-11","conditions":"Sleep Disorders","enrollment":50},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593},{"nctId":"NCT00740389","phase":"PHASE1","title":"TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-09","conditions":"HIV, AIDS, Fungal Infection","enrollment":18},{"nctId":"NCT00767117","phase":"PHASE1","title":"TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-09","conditions":"HIV","enrollment":16},{"nctId":"NCT00828815","phase":"PHASE1","title":"TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-03","conditions":"HIV, Pharmacokinetics","enrollment":22},{"nctId":"NCT00111280","phase":"PHASE2","title":"TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2004-09","conditions":"HIV Infection","enrollment":48},{"nctId":"NCT00225303","phase":"PHASE2","title":"TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-03","conditions":"HIV Infection","enrollment":116},{"nctId":"NCT00855088","phase":"PHASE1","title":"Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-07","conditions":"HIV/AIDS, HIV Infections","enrollment":13},{"nctId":"NCT01121809","phase":"PHASE4","title":"Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2010-04","conditions":"HIV-1 Infection, HIV Infections","enrollment":16},{"nctId":"NCT00871234","phase":"PHASE1","title":"Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study","status":"COMPLETED","sponsor":"Indiana University","startDate":"2009-04","conditions":"Endothelial Function, Lipids, Insulin Resistance","enrollment":28},{"nctId":"NCT00460382","phase":"PHASE2","title":"Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":103},{"nctId":"NCT00920296","phase":"PHASE1","title":"DDI Study of Etravirine and GSK1265744","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Healthy Subjects, Infection, Human Immunodeficiency Virus","enrollment":12},{"nctId":"NCT00081978","phase":"PHASE2","title":"TMC125-C223: TMC125 in HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2004-03","conditions":"HIV Infection","enrollment":211},{"nctId":"NCT00412646","phase":"PHASE2","title":"TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2002-06","conditions":"Anti-Retroviral Agents, HIV-1","enrollment":260},{"nctId":"NCT00792324","phase":"PHASE3","title":"Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2008-06","conditions":"HIV","enrollment":24},{"nctId":"NCT00774111","phase":"PHASE1","title":"GSK1349572 Drug Interaction Study With Etravirine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10","conditions":"Healthy Subjects","enrollment":16},{"nctId":"NCT00531323","phase":"PHASE1","title":"TMC 125 Blood Levels Study","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2007-09","conditions":"HIV Infections","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":84,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TMC125","genericName":"TMC125","companyName":"Tibotec Pharmaceuticals, Ireland","companyId":"tibotec-pharmaceuticals-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication. Used for Treatment of HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}